Traws Pharma's Q2 2025 Earnings Call: Unraveling Contradictions in Narazaciclib Trials and Future Prospects

Narazaciclib trial status and timing, trial progress and patient enrollment, endometrial cancer trial and CDK 4/6 activity, rigosertib and endometrial cancer trial timelines, and efficacy data anticipation are the key contradictions discussed in Traws Pharma's latest 2025Q2 earnings call.



COVID Program Reprioritization:
- Traws Pharma reprioritized its clinical trial plans, focusing on short- and medium-term shareholder value.
- This included submitting a Phase II study of ratutrelvir for COVID-19 treatment, aiming to report results by year-end 2025, and evaluating ratutrelvir in PAXLOVID-ineligible patients.

Increased PAXLOVID Sales:
- Pfizer reported $427 million in sales of PAXLOVID in Q2 2025, representing a 70% increase compared to the same period in the prior year.
- The growth was attributed to increased demand for COVID-19 treatments and the effectiveness of PAXLOVID as a therapy.

Influenza Program and BARDA Discussions:
- Traws Pharma continues constructive discussions with BARDA regarding the inclusion of tivoxavir marboxil (TXM) in the drug stockpiling initiative for influenza, including bird flu.
- The aim is to maximize short- and medium-term commercial potential for this program, given the low immediate likelihood of successfully recruiting a Phase II study.

R&D Expense Decline and Financial Improvement:
- Research and development expense for the second quarter of 2025 totaled $2.3 million, down from $4 million in the comparable period of 2024.
- The decrease was primarily due to a reduction in expenses related to the oncology program and a decrease in personnel expenses, which contributed to an improved financial position.

Revenue from Licensing Agreement Termination:
- Revenue for the quarter ended June 30, 2025, was $2.7 million, compared to $57,000 for the same period in 2024.
- The increase was due to $2.7 million in deferred revenue, recognized as revenue in the second quarter, related to the mutual termination of a licensing agreement associated with the legacy oncology program.